Marijuana legalization in several states forced employers to rethink zero-tolerance drug policies. Psychedelic therapy is next, and it may be even more complicated for employers to navigate.
Right now, employers face little risk in disciplining employees for off-duty psychedelic use. Psilocybin, MDMA, and LSD are still Schedule I, which means the federal government considers them to have no accepted medical use. No state protects psychedelic users the way many now protect marijuana users. That gives employers a clear legal basis for strict policies with no accommodation analysis required. The mechanism that makes this classification so powerful for employers is the Americans with Disabilities Act (“ADA”) “illegal use of drugs” exclusion (42 U.S.C. § 12114): the statute excludes from its protections any individual “currently engaging in the illegal use of drugs.” For decades, courts have applied that exclusion categorically to Schedule I substances — if a drug has no accepted medical use under federal law, any use of it is per se “illegal,” and the employer owes no duty to accommodate under ADA, regardless of what state law permits. No interactive process, no individualized assessment, no undue-hardship analysis: the inquiry ends at “Schedule I.”
An April 2026 Executive Order signals a possible path to Schedule III for psychedelic therapy — and that shift would dismantle the defense described above. Schedule III substances are recognized as having accepted medical uses; once a substance carries that status, the ADA’s “illegal use” exclusion no longer applies and the employer’s categorical defense collapses. Employers are already grappling with this in the marijuana context following the DEA’s April 2026 rescheduling of state-licensed medical marijuana to Schedule III. An FDA approved, rescheduled psychedelic would be a lawful prescription medication in every sense — triggering ADA reasonable accommodation duties, anti-discrimination protections, and potential state-law off-duty conduct protections.
We’ve seen this before with marijuana. States like California, New York, and New Jersey already prohibit adverse action based solely on off-duty use. Many employers have already shifted away from metabolite testing toward observational impairment assessments and documented fitness-for-duty evaluations, paired with testing that detects current impairment rather than past use — an approach that will likely carry over to psychedelics. One key difference is that while testing for current marijuana impairment is now more accessible, comparable testing for psychedelics remains limited and expensive.
The takeaway for employers:
- Shift from testing for substances to testing for impairment — at least for non-safety-sensitive roles.
- Train supervisors to recognize objective signs of impairment.
- Establish reasonable-suspicion protocols.
- Document consistently; this approach is more defensible and more adaptable as more substances become legal prescriptions.
Safety-sensitive roles are different. Department of Transportation regulated and other high-risk positions have federal requirements that override state protections. Employers can enforce strict impairment policies here — and the ADA’s “direct threat” analysis still lets employers deny accommodations when medication poses a significant safety risk. But both the safety-sensitive designation and direct threat determination must be individualized and evidence-based, not blanket categories or stereotypes.
Psychedelic therapy is not mainstream yet, but the regulatory developments are worth watching. Employers who navigated marijuana legalization successfully have a head start here. Audit your drug policies. Train supervisors on impairment recognition. Build individualized processes for safety-sensitive roles. Getting ahead of this shift now means less disruption later.
